Completed PHASE2 INTERVENTIONAL 2-arm NCT02230670

A Study of IDN-6556 in Subjects With Liver Cirrhosis (LC)

A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis

Sponsor: Conatus Pharmaceuticals Inc.

Conditions Hepatic Cirrhosis Liver Cirrhosis

Interventions IDN-6556 Placebo

Updated 7 times since 2017 Last updated: Jun 6, 2017 Started: Aug 31, 2014 Primary completion: Jan 31, 2016 Completion: Jan 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02230670, this PHASE2 trial focuses on Hepatic Cirrhosis and Liver Cirrhosis and remains completed. Sponsored by Conatus Pharmaceuticals Inc., it has been updated 7 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Aug 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Aug 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Aug 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Conatus Pharmaceuticals Inc.

Data source: Conatus Pharmaceuticals Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Birmingham, United States , Chicago, United States , Cincinnati, United States , Detroit, United States , Fort Worth, United States , Gainesville, United States , Houston, United States , Indianapolis, United States , La Jolla, United States and 14 more locations